Minneapolis, Minnesota, United States, March 2026 — Natus Neuro has announced that Michael Owens has started a new position as Chief Technology Officer. In this role, he will lead technology direction and innovation priorities, bringing a strong foundation in technology leadership, cloud computing, artificial intelligence (AI), and innovation.
With extensive experience across R&D leadership and medical devices innovation, Michael Owens steps into the CTO role to support Natus Neuro’s focus on advancing neurodiagnostic and neurocritical solutions. His background reflects deep expertise in leading R&D organizations, strengthening product development, and driving end-to-end innovation programs.
Michael Owens joins Natus Neuro at a time when technology, connected platforms, and data-driven capabilities are increasingly central to clinical workflows across neurodiagnostics and monitoring. His appointment aligns with the company’s continued focus on enabling innovation and scalable execution through strong technology leadership.
Michael Owens has begun his journey at Natus Neuro as Chief Technology Officer, based in Minneapolis, Minnesota, United States, where he will contribute to technology strategy and execution across the organization.
Before joining Natus Neuro, he built deep R&D and innovation leadership at Philips, where he led R&D and end-to-end innovation programs while supporting business unit priorities, operational leadership, and site-level leadership responsibilities.
Earlier, he contributed to innovation and R&D leadership at Spectranetics, where his responsibilities expanded from platform-focused R&D leadership into broader cross-functional program leadership and functional leadership across multiple cardiovascular and peripheral vascular technology areas.
Prior to this, he held R&D leadership responsibilities at Covidien (Medtronic Minimally Invasive Therapies Group), where his work included leading R&D for vascular technology development and supporting programs aimed at improving delivery systems and clinical usability.
Earlier in his career, he worked with Boston Scientific, contributing as a core-team member on clinical product development programs and supporting innovation and development efforts for drug eluting and drug elution technology programs. He also built early technical foundations at Dow Corning, progressing through roles in R&D and chemistry.
About Natus Neuro
Natus’ portfolio includes neurodiagnostic and monitoring solutions including EEG, LTM, ICU, PSG, EMG, EP. Neurocritical solutions include intracranial pressure (ICP) monitoring and external ventricular drainage.
Natus does not endorse personal/non-work related comments made by employees on social media. Further, Natus values the respect and inclusion of all people without regard to race, color, religion, sex, national origin, veteran status, disability, sexual orientation, gender identity, or any other protected status.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
